President Donald Trump announced new tariffs of up to 100% on imported pharmaceuticals and modified tariffs on metals to prevent trade circumvention, as part of his renewed trade strategy.
100% Tariff on Foreign Drugs
- The tariff applies to imported patented drugs and their active ingredients from companies not participating in the "Most Favored Nation" (MFN) pricing initiative.
- Implementation timeline: 120 days for large companies, 180 days for small firms.
- Goal: Pressure foreign manufacturers to produce in the U.S. and sell drugs directly to consumers.
- Exemptions: Companies joining the MFN initiative or relocating production to the U.S. face reduced tariffs (e.g., 20% for production shift).
- Countries with existing trade agreements: EU, Japan, South Korea, and Switzerland at 15%; UK at 10%.
Metal Tariff Modifications
- Steel, copper, and aluminum tariffs increased to 50%, based on the actual price paid by U.S. consumers rather than declared values.
- Aimed at foreign sellers who deliberately undervalue exports to minimize tariff payments.
- Products containing significant metal content (e.g., washing machines) now face a 25% tariff if metal constitutes a certain proportion of total weight.
Context and Reactions
- These measures follow a Supreme Court ruling that limited Trump's previous broad tariff authority.
- The administration has secured deals with over a dozen pharmaceutical companies for direct sales under MFN, with three-year tariff exemptions in exchange for U.S. manufacturing investment.
- Concerns within the Republican Party focus on potential price increases for Americans amid cost-of-living pressures.
- An official dismissed major affordability impacts, stating the revised metal tariffs would have minimal effect on consumer access.